Title : Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.

Pub. Date : 2014

PMID : 24983357






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 We analyzed BCL-2 family member expression levels of 34 samples from 17 patients collected before and 10 to 14 days after treatment initiation with either vemurafenib or dabrafenib/trametinib combination. dabrafenib BCL2 apoptosis regulator Homo sapiens